Manchester Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Manchester Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$25K	Sell	83 -3	-3%	-$905	﹤0.01%	651
2026 Q1	$28.5K	Buy	86 +2	+2%	+$681	﹤0.01%	605
2025 Q4	$33.4K	Buy	84 +72	+600%	+$31.9K	﹤0.01%	564
2025 Q3	$5.47K	Buy	12 +9	+300%	+$3.67K	﹤0.01%	941
2025 Q2	$979	Buy	3 +1	+50%	+$277	﹤0.01%	1063
2025 Q1	$541	Hold	2	–	–	﹤0.01%	1081
2024 Q4	$471	Hold	2	–	–	﹤0.01%	1084
2024 Q3	$551	Hold	2	–	–	﹤0.01%	1077
2024 Q2	$486	Sell	2 -1	-33%	-$158	﹤0.01%	1062
2024 Q1	$449	Hold	3	–	–	﹤0.01%	949
2023 Q4	$575	Hold	3	–	–	﹤0.01%	901
2023 Q3	$532	Hold	3	–	–	﹤0.01%	897
2023 Q2	$570	Buy	+3	New	+$595	﹤0.01%	869
2020 Q4	–	Sell	-3	Closed	–	–	729
2020 Q3	$0	Buy	+3	New	+$426	﹤0.01%	549

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Manchester Capital Management's ALNY Position: Q2 2026 in Review

Manchester Capital Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 3.5% in Q2 2026, selling an estimated $905 and leaving 83 shares worth $25K. The position accounts for ﹤0.01% of the portfolio, ranked #651.

Manchester Capital Management first reported a position in ALNY in Q3 2020 and has held it in 14 quarters since. The position peaked at $33.4K in Q4 2025. 791 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Manchester Capital Management held 83 shares of Alnylam Pharmaceuticals worth $25K as of Q2 2026.
Manchester Capital Management sold 3 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $905.
Alnylam Pharmaceuticals made up ﹤0.01% of Manchester Capital Management's portfolio in Q2 2026, its #651 holding.
Manchester Capital Management first reported a position in Alnylam Pharmaceuticals in Q3 2020 and has held it in 14 quarters since.
Manchester Capital Management's Alnylam Pharmaceuticals position peaked at $33.4K in Q4 2025.
791 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Manchester Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.